Price Is GSK’s Weapon Ahead Of Tanzeum Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline has priced its once-weekly GLP-1 agonist Tanzeum 64% below the high dose of Novo Nordisk’s market-leading, once-daily Victoza – a sign of the uphill commercial battle it faces against an entrenched rival.